Rituximab stabilizes multifocal motor neuropathy increasingly less responsive to IVIg.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 15596777.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The authors report a patient with anti-GM(1) antibody-negative multifocal motor neuropathy (MMN) who was increasingly less responsive to IV immunoglobulins (IVIgs). Five yearly courses of the monoclonal anti-CD20 antibody rituximab were well tolerated and extended the interval of IVIg administration from 7 to 12 days (corresponding to 42% reduction of IVIg) during this period. Rituximab may be a benefit for patients with MMN.
Medical subject headings
- Antibodies, Monoclonal
- Demyelinating Diseases
- Immunization, Passive
- Immunoglobulins, Intravenous
- Polyneuropathies